{"id":"W4410979871","doi":"10.1016/j.jtho.2025.05.020","title":"LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Eisai Canada; Eisai; MSD","keywords":"Medicine; Pembrolizumab; Lenvatinib; Oncology; Chemotherapy; Platinum; Internal medicine; PD-L1; Immunotherapy; Cancer; Hepatocellular carcinoma; Sorafenib","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001775649,0.0006875562,0.00130724,0.0004263477,0.00026779,0.0006783288,0.0008895218,0.0008106859,0.008693203],"category_scores_gemma":[0.00106661,0.0003868271,0.001098446,0.0003299775,0.0005131251,0.0008029588,0.0003989933,0.002412098,0.001012814],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001242809,"about_ca_system_score_gemma":0.001329428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007988362,"about_ca_topic_score_gemma":0.003193479,"domain_scores_codex":[0.9993777,0.0003107388,0.0000492271,0.0001048723,0.00009061108,0.00006672379],"domain_scores_gemma":[0.9994892,0.0001352334,0.0001349401,0.00002054638,0.00003325749,0.0001868164],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8572571,0.007750113,0.003807183,0.002557524,0.00206028,0.0001972585,0.0001020788,0.001183981,0.01184613,0.0003435892,0.004683572,0.1082112],"study_design_scores_gemma":[0.8577919,0.1191058,0.01032419,0.0001958366,0.001137551,0.0003506466,0.00003568831,0.001127318,0.002370792,0.0002681066,0.007264747,0.00002741217],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9730768,0.01096105,0.0008829231,0.001193366,0.0003364343,0.004783235,0.00314042,0.0001853477,0.005440543],"genre_scores_gemma":[0.9842811,0.003041003,0.001536781,0.001002435,0.0001775091,0.004293886,0.002152806,0.0000186251,0.003495906],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008693203,"threshold_uncertainty_score":0.02908158,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05813767730453691,"score_gpt":0.3986231119463125,"score_spread":0.3404854346417756,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}